Research highlights of clinical oncology early 2022
Author:
Open Access
- 5 July 2022
- journal article
- review article
- Published by Springer Nature in Holistic Integrative Oncology
- Vol. 1 (1) , 1-5
Abstract
Advance in clinical oncology is highly relied on development of cancer research and clinical trials. There has been ample evidence regarding the new therapeutic drugs, agents or techniques for the treatment of cancer. We did a broad literature search to catch the latest progress in the cancer therapy. Here is a brief review of the newly released results of clinical trials including surgical modalities, immune checkpoint blockade, chimeric antigen receptor T-cell (CAR T) therapy, antibody–drug conjugates and tumor vaccines, etc. Biomarkers or patient assessment of cancer therapy were also discussed.Keywords
This publication has 22 references indexed in Scilit:
- Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian CancerNew England Journal of Medicine, 2021
- Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau DiseaseNew England Journal of Medicine, 2021
- Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trialNature Medicine, 2021
- Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trialNature Medicine, 2021
- Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trialNature Medicine, 2021
- Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised studyThe Lancet, 2021
- CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trialNature Medicine, 2021
- Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trialNature Medicine, 2021
- Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung CancerNew England Journal of Medicine, 2021
- Immunostimulation with chemotherapy in the era of immune checkpoint inhibitorsNature Reviews Clinical Oncology, 2020